Senetek licenses Invicorp ED treatment to Plethora

UK company Senetek has granted an exclusive licence to Plethora Solutions for the manufacture and marketing in North America of Invicorp, Senetek's patented combination drug treatment for male erectile dysfunction (ED).

Under the terms of the agreement, Plethora assumes full responsibility for the drug regulatory process for Invicorp and for establishing the therapy in the North American market, which represents some 40% of global sales of ED treatments, and is granted options on additional non-North American markets outside the EU. Senetek will receive royalties based on Plethora's and its sub-licensees' net sales of Invicorp plus predetermined milestone payments upon achievement of regulatory approvals and cumulative net sales targets.

Invicorp is an injectable combination of phentolamine mesylate and vasoactive intestinal polypeptide for the treatment of ED. The product has already received marketing authorisation in Denmark, which has been chosen as the Reference Member State for the Mutual Recognition Procedure in Europe, as well as the UK.

'Invicorp has great potential in the management of the large number of patients who have a poor or inadequate response to oral drugs and those patients who cannot safely take them,' said Dr Mike Wyllie, founder and chief scientific officer of Plethora. 'In this respect, Invicorp could become an attractive treatment option for many patients.'